Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
VeonGen Therapeutics GmbH logo — Dedicated to develop the medicines of the future

VeonGen Therapeutics GmbH

Dedicated to develop the medicines of the future

Founded 2017 Germany Planegg, Germany 9 employees Series A Biotechnology, Health Care +1

General Information

Company Name VeonGen Therapeutics GmbH
Founded Year 2017
Location Germany Planegg, Germany
Employees 9
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Series A
Business Model B2B, Platform
Revenue Model Licensing, Project Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with VeonGen Therapeutics GmbH. To contact VeonGen Therapeutics GmbH, visit veongen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does VeonGen Therapeutics GmbH compare?

A PDF of VeonGen Therapeutics GmbH and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting VeonGen Therapeutics GmbH soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About VeonGen Therapeutics GmbH

VeonGen Therapeutics GmbH, founded in 2017 as a spin-off from Ludwig-Maximilians-University Munich, is a pioneering force in the Biotechnology and Health Care sectors. Based in Germany, the company is committed to developing next-generation therapies with its slogan "Dedicated to develop the medicines of the future."

VeonGen leverages two unique and proprietary technology platforms to address unmet medical needs with in-house gene therapy programs, specifically targeting retinal disorders. The company's strategy also includes collaborative efforts to expand the application of its technologies to other medical indications.

In November 2019, VeonGen raised a Series A investment, backed by significant players such as WuXi AppTec and Sequoia Capital China. This investment underlines the confidence in VeonGen's innovative approach and its potential to revolutionize gene therapies. Investors will find VeonGen's cutting-edge technologies and strategic partnerships compelling as a prospective addition to their portfolios.

Business keywords: Gene Therapy, AAV Vector Technology, Retinal Disorders, Ophthalmic Diseases, Biopharmaceutical Partnerships, vgAAV Platform, REVeRT Platform, Intravitreal Administration, Transduction Efficiency, Large Gene Mutations, Clinical Ophthalmic Programs, Innovative Therapies, Proprietary Technology, Unmet Medical Needs, Spin-off

Services & Products

Development of novel gene therapy platforms
Creating in-house pipeline for ophthalmic gene therapy
Partnering with biopharmaceutical companies
Overcoming limitations of existing AAV-based therapies

Target Customers

Biopharmaceutical companies Healthcare providers focusing on genetic and ophthalmic diseases Research institutions in genetic engineering and therapeutics

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A Undisclosed 2
WuXi AppTec
WuXi AppTec, Sequoia Capital China
29 Nov 2019

VeonGen Therapeutics GmbH Alternatives & Competitors

View All Alternatives
VeonGen Therapeutics GmbH vs
AAVantgarde
AAVantgarde

Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease

Series A
70 employees
Biotechnology, Health Care
VeonGen Therapeutics GmbH vs
GenSight Biologics
GenSight Biologics France

Applying pathbreaking science to transform the lives of patients with severe retinal neurodegenerati...

Post-IPO Equity
34 employees
Biotechnology, Health Care
VeonGen Therapeutics GmbH vs
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. United States

This company is now integrated into the Roche Group, united in our commitment to do now what patient...

Acquired
304 employees
Biotechnology, Health and Wellness
Also compare with: VeonGen Therapeutics GmbH vs Annexon Biosciences Annexon Biosciences View all alternatives

FAQ About VeonGen Therapeutics GmbH

Dedicated to develop the medicines of the future
VeonGen Therapeutics GmbH was founded in 2017.
VeonGen Therapeutics GmbH is headquartered in Planegg, Germany.
VeonGen Therapeutics GmbH operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Gene Therapy, AAV Vector Technology, Retinal Disorders and Ophthalmic Diseases. Its customers include Biopharmaceutical companies, Healthcare providers focusing on genetic and ophthalmic diseases and Research institutions in genetic engineering and therapeutics.
VeonGen Therapeutics GmbH has a B2B and Platform business model. Its revenue comes from Licensing, Project Based and Product Sales.
VeonGen Therapeutics GmbH has approximately 9 employees.
VeonGen Therapeutics GmbH has completed 1 funding round. The latest funding stage is Series A.
VeonGen Therapeutics GmbH offers: Development of novel gene therapy platforms, Creating in-house pipeline for ophthalmic gene therapy, Partnering with biopharmaceutical companies, Overcoming limitations of existing AAV-based therapies.
Top alternatives and competitors to VeonGen Therapeutics GmbH include AAVantgarde, GenSight Biologics, Spark Therapeutics, Inc., Annexon Biosciences, Ocular Therapeutix, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VeonGen Therapeutics GmbH and AAVantgarde are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for VeonGen Therapeutics GmbH, https://bouncewatch.com/company/vigeneron, updated 14 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes